PlainRecalls
FDA Drug Moderate Class II Terminated

Cefdinir for Oral Suspension USP, 250mg/5mL, packaged in a) 60mL (NDC 68180-723-20), b)100mL (NDC 68180-723-10), Rx Only, Manufactured for: Lupin Pharmaceuticals Inc. Baltimore, MD 21202; Manufactured by: Lupin Limited Mandideep 462 046 INDIA

Reported: January 16, 2019 Initiated: January 2, 2019 #D-0376-2019

Product Description

Cefdinir for Oral Suspension USP, 250mg/5mL, packaged in a) 60mL (NDC 68180-723-20), b)100mL (NDC 68180-723-10), Rx Only, Manufactured for: Lupin Pharmaceuticals Inc. Baltimore, MD 21202; Manufactured by: Lupin Limited Mandideep 462 046 INDIA

Reason for Recall

CGMP Deviations: Product complaints received indicating reconstituted suspension was observed to be thick.

Details

Units Affected
287,784 bottles
Distribution
Nationwide within the United States
Location
Baltimore, MD

Frequently Asked Questions

What product was recalled?
Cefdinir for Oral Suspension USP, 250mg/5mL, packaged in a) 60mL (NDC 68180-723-20), b)100mL (NDC 68180-723-10), Rx Only, Manufactured for: Lupin Pharmaceuticals Inc. Baltimore, MD 21202; Manufactured by: Lupin Limited Mandideep 462 046 INDIA. Recalled by Lupin Pharmaceuticals Inc.. Units affected: 287,784 bottles.
Why was this product recalled?
CGMP Deviations: Product complaints received indicating reconstituted suspension was observed to be thick.
Which agency issued this recall?
This recall was issued by the FDA Drug on January 16, 2019. Severity: Moderate. Recall number: D-0376-2019.